• 1
    Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 1994; 204: 1- 15.
  • 2
    Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. HEPATOLOGY 1992; 16: 707- 714.
  • 3
    Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268- 1274.
  • 4
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548- 1554.
  • 5
    Häussinger D, Hallbrucker C, Saha N, Lang F, Gerok W. Cell volume and bile acid excretion. Biochem J 1992; 288( Pt 2): 681- 689.
  • 6
    Schliess F, Kurz AK, vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997; 113: 1306- 1314.
  • 7
    Graf D, Kurz AK, Fischer R, Reinehr R, Häussinger D. Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner. Gastroenterology 2002; 122: 1411- 1427.
  • 8
    Benz C, Angermuller S, Kloters-Plachky P, Sauer P, Stremmel W, Stiehl A. Effect of S-adenosylmethionine versus tauroursodeoxycholic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes. Eur J Clin Invest 1998; 28: 577- 583.
  • 9
    Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203- 211.
  • 10
    Queneau PE, Montet JC. Hepatoprotection by hydrophilic bile salts. J Hepatol 1994; 21: 260- 268.
  • 11
    Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. HEPATOLOGY 2001; 33: 1206- 1216.
  • 12
    Häussinger D, Kurz AK, Wettstein M, Graf D, Vom Dahl S, Schliess F. Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis. Gastroenterology 2003; 124: 1476- 1487.
  • 13
    Häussinger D, Saha N, Hallbrucker C, Lang F, Gerok W. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver. Biochem J 1993; 291: 355- 360.
  • 14
    vom Dahl S, Schliess F, Reissmann R, Görg B, Weiergraber O, Kocalkova M, et al. Involvement of integrins in osmosensing and signaling toward autophagic proteolysis in rat liver. J Biol Chem 2003; 278: 27088- 27095.
  • 15
    Schliess F, Reissmann R, Reinehr R, vom Dahl S, Häussinger D. Involvement of integrins and Src in insulin signaling toward autophagic proteolysis in rat liver. J Biol Chem 2004; 279: 21294- 21301.
  • 16
    Kubitz R, D'Urso D, Keppler D, Häussinger D. Osmodependent dynamic localization of the multidrug resistance protein 2 in the rat hepatocyte canalicular membrane. Gastroenterology 1997; 113: 1438- 1442.
  • 17
    Schmitt M, Kubitz R, Lizun S, Wettstein M, Häussinger D. Regulation of the dynamic localization of the rat Bsep gene-encoded bile salt export pump by anisoosmolarity. HEPATOLOGY 2001; 33: 509- 518.
  • 18
    Reinehr R, Gohlke H, Sommerfeld A, Vom Dahl S, Häussinger D. Activation of integrins by urea in perfused rat liver. J Biol Chem 2010; 285: 29348- 29356.
  • 19
    Volpes R, van den Oord JJ, Desmet VJ. Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol 1993; 142: 1483- 1492.
  • 20
    Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59- 67.
  • 21
    Puklin-Faucher E, Gao M, Schulten K, Vogel V. How the headpiece hinge angle is opened: New insights into the dynamics of integrin activation. J Cell Biol 2006; 175: 349- 360.
  • 22
    Puklin-Faucher E, Vogel V. Integrin activation dynamics between the RGD-binding site and the headpiece hinge. J Biol Chem 2009; 284: 36557- 36568.
  • 23
    Sies H. The use of perfusion of liver and other organs for the study of microsomal electron-transport and cytochrome P-450 systems. Methods Enzymol 1978; 52: 48- 59.
  • 24
    vom Dahl S, Hallbrucker C, Lang F, Häussinger D. Regulation of cell volume in the perfused rat liver by hormones. Biochem J 1991; 280( Pt 1): 105- 109.
  • 25
    Kullak-Ublick GA, Ismair MG, Kubitz R, Schmitt M, Häussinger D, Stieger B, et al. Stable expression and functional characterization of a Na+-taurocholate cotransporting green fluorescent protein in human hepatoblastoma HepG2 cells. Cytotechnology 2000; 34: 1- 9.
  • 26
    Kubitz R, Huth C, Schmitt M, Horbach A, Kullak-Ublick G, Häussinger D. Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells. HEPATOLOGY 2001; 34: 340- 350.
  • 27
    Kuhlkamp T, Keitel V, Helmer A, Häussinger D, Kubitz R. Degradation of the sodium taurocholate cotransporting polypeptide (NTCP) by the ubiquitin-proteasome system. Biol Chem 2005; 386: 1065- 1074.
  • 28
    Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005; 44: 262- 273.
  • 29
    Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999; 274: 8335- 8343.
  • 30
    Reinehr R, Sommerfeld A, Häussinger D. Insulin induces swelling-dependent activation of the epidermal growth factor receptor in rat liver. J Biol Chem 2010; 285: 25904- 25912.
  • 31
    Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151- 155.
  • 32
    Xiong JP, Stehle T, Goodman SL, Arnaout MA. A novel adaptation of the integrin PSI domain revealed from its crystal structure. J Biol Chem 2004; 279: 40252- 40254.
  • 33
    Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318- 328.
  • 34
    Cruz LN, Guerra MT, Kruglov E, Mennone A, Garcia CRS, Chen J, et al. Regulation of multidrug resistance-associated protein 2 by calcium signaling in mouse liver. HEPATOLOGY 2010; 52: 327- 337.
  • 35
    Wimmer R, Hohenester S, Pusl T, Denk GU, Rust C, Beuers U. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut 2008; 57: 1448- 1454.
  • 36
    Mould AP, Barton SJ, Askari JA, McEwan PA, Buckley PA, Craig SE, et al. Conformational changes in the integrin beta A domain provide a mechanism for signal transduction via hybrid domain movement. J Biol Chem 2003; 278: 17028- 17035.
  • 37
    Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25: 619- 647.
  • 38
    Chen W, Lou J, Hsin J, Schulten K, Harvey SC, Zhu C. Molecular dynamics simulations of forced unbending of integrin alpha(v)beta. PLoS Comput Biol 2011; 7: e1001086.
  • 39
    Puklin-Faucher E, Sheetz MP. The mechanical integrin cycle. J Cell Sci 2009; 122: 179- 186.
  • 40
    Craig D, Gao M, Schulten K, Vogel V. Structural insights into how the MIDAS ion stabilizes integrin binding to an RGD peptide under force. Structure 2004; 12: 2049- 2058.
  • 41
    Murcia M, Jirouskova M, Li J, Coller BS, Filizola M. Functional and computational studies of the ligand-associated metal binding site of beta3 integrins. Proteins 2008; 71: 1779- 1791.